Philip Morris seals deal for UK's Vectura despite health group concerns
Send a link to a friend
[September 16, 2021] By
Pushkala Aripaka and Siddharth Cavale
(Reuters) -Cigarette maker Philip Morris (PMI)
clinched its 1.1 billion-pound takeover of asthma inhaler maker Vectura
on Thursday, winning the support of the British company's shareholders
despite the concerns of health professionals.
Vectura's shareholders decided to take the 165 pence-per-share offer
from PMI, with nearly 75% backing the deal.
Buying the London-listed inhaler maker is part of Philip Morris' long
term plan to develop "smoke-free" products and switch to being a
"broader healthcare and wellness" company.
But it has angered health groups such as Asthma UK and the British Lung
Foundation that have questioned whether a tobacco group should own a
company that cures the very respiratory illnesses cigarettes cause.
PMI Chief Executive Jacek Olczak has argued that acquiring Vectura is a
critical part of his strategy to move the company "Beyond Nicotine".
He told the Telegraph last month that opponents of the deal were "not
interested in progress" and accused them of "settling old scores" with
the tobacco industry.
Olczak said on Thursday PMI would provide Vectura's scientists with the
resources and expertise to reach its goal of generating at least $1
billion in net revenue from "Beyond Nicotine" products by 2025.
In the meantime, Asthma UK and the British Lung Foundation said they
have sent a letter urging the government to look into any conflict of
interest issues.
The letter was co-signed by 35 charities, public health experts and
clinicians.
[to top of second column] |
Philip Morris International's research and development headquarters
are pictured next to the company's cigarette factory in Neuchatel,
Switzerland, March 17, 2017. Picture take March 17, 2017. REUTERS/Paritosh
Bansal/File Photo
"There's now a very real risk that Vectura's deal with big tobacco will lead to
the cigarette industry wielding undue influence on UK health policy," said Sarah
Woolnough, Chief Executive of Asthma UK and the British Lung Foundation.
"We call on the government to stand by its commitment to the World Health
Organization Framework Convention on Tobacco Control to prevent this happening,"
Woolnough added.
PMI has received regulatory clearances for the deal and following the public
tender process, its offer cannot now be withdrawn.
While the company received the 50% threshold to make its offer unconditional, it
has not yet reached the 75% of shares it needs to delist Vectura.
PMI said it was extending its offer to Sept 30., to give Vectura shareholders
time to accept its proposal.
"Phillip Morris isn't ignoring the elephant; it's making us all take a long hard
look. Discomfort is good, it tends to deliver change, but care must be taken
that the promised change does come and there are no detours on the journey," AJ
Bell financial analyst Danni Hewson said.
($1 = 0.7234 pounds)
(Reporting by Pushkala Aripaka and Siddharth Cavale in Bengaluru;Editing by
Elaine Hardcastle)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |